Literature DB >> 14872022

Plasma testosterone levels in Alzheimer and Parkinson diseases.

M S Okun1, M R DeLong, J Hanfelt, M Gearing, A Levey.   

Abstract

BACKGROUND: Testosterone deficiency, a treatable condition commonly seen in aging men, has been linked to Parkinson disease (PD) and Alzheimer disease (AD). In normal subjects, low testosterone levels are associated with cognitive and neuropsychiatric symptoms, yet the relationship between testosterone levels and cognitive function in PD and AD remains unclear.
OBJECTIVE: To examine the relationship of testosterone levels to age and cognitive function in PD and AD.
METHODS: Plasma testosterone levels were determined in men enrolled in a clinical registry of subjects with PD and AD, and neuropsychological testing was performed on subjects who consented. Testosterone levels in men with PD were compared with those in men with AD. In both groups, the relationship between testosterone levels and neuropsychological test scores was analyzed, adjusting for age and education.
RESULTS: Linear regression analysis revealed that testosterone levels decreased with age in male PD patients (p < 0.03) and male AD patients (p < 0.07). The rate of decline was similar for the two groups. In PD patients, lower testosterone levels were associated with poorer performance on Trails B Seconds (p < 0.02).
CONCLUSIONS: There is a similar age-related decline in plasma testosterone levels in men with either PD or AD. Previously described associations between low testosterone levels and frontal lobe dysfunction in normal aged men, together with these results, suggest that the hormonal deficiency may act as a "second hit" to impair cognitive function in neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14872022     DOI: 10.1212/01.wnl.0000106840.72938.84

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Androgens, aging, and Alzheimer's disease.

Authors:  Christian J Pike; Emily R Rosario; Thuy-Vi V Nguyen
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

2.  Oxidative stress defines the neuroprotective or neurotoxic properties of androgens in immortalized female rat dopaminergic neuronal cells.

Authors:  Shaletha Holmes; Babak Abbassi; Chang Su; Meharvan Singh; Rebecca L Cunningham
Journal:  Endocrinology       Date:  2013-08-19       Impact factor: 4.736

Review 3.  Testosterone deficiency, insulin-resistant obesity and cognitive function.

Authors:  Hiranya Pintana; Nipon Chattipakorn; Siriporn Chattipakorn
Journal:  Metab Brain Dis       Date:  2015-02-24       Impact factor: 3.584

4.  Estrogen, testosterone, and sequential movement in men.

Authors:  Jessica A Siegel; Laura A Young; Michelle B Neiss; Mary H Samuels; Charles E Roselli; Jeri S Janowsky
Journal:  Behav Neurosci       Date:  2008-10       Impact factor: 1.912

5.  Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates.

Authors:  Eric R Braverman; Thomas J H Chen; Thomas J Prihoda; William Sonntag; Brian Meshkin; B William Downs; Julie F Mengucci; Seth H Blum; Alison Notaro; Vanessa Arcuri; Michael Varshavskiy; Kenneth Blum
Journal:  Age (Dordr)       Date:  2007-05-12

Review 6.  Androgen cell signaling pathways involved in neuroprotective actions.

Authors:  Christian J Pike; Thuy-Vi V Nguyen; Martin Ramsden; Mingzhong Yao; M Paul Murphy; Emily R Rosario
Journal:  Horm Behav       Date:  2007-11-22       Impact factor: 3.587

Review 7.  Neurodegeneration and ageing in the HAART era.

Authors:  Bruce J Brew; S M Crowe; A Landay; Lucette A Cysique; Gilles Guillemin
Journal:  J Neuroimmune Pharmacol       Date:  2008-12-06       Impact factor: 4.147

Review 8.  Weight loss in neurodegenerative disorders.

Authors:  N A Aziz; M A van der Marck; H Pijl; M G M Olde Rikkert; B R Bloem; R A C Roos
Journal:  J Neurol       Date:  2009-01-22       Impact factor: 4.849

9.  Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort.

Authors:  Michael S Okun; Samuel S Wu; Dana Jennings; Kenneth Marek; Ramon L Rodriguez; Hubert H Fernandez
Journal:  J Clin Mov Disord       Date:  2014-11-26

10.  Testosterone ameliorates age-related brain mitochondrial dysfunction.

Authors:  Wensheng Yan; Tianyun Zhang; Yunxiao Kang; Guoliang Zhang; Xiaoming Ji; Xu Feng; Geming Shi
Journal:  Aging (Albany NY)       Date:  2021-06-17       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.